Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001737287-25-000004
Filing Date
2025-01-28
Accepted
2025-01-28 20:10:50
Documents
3
Period of Report
2025-01-24

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1738113042.html 4  
1 FORM 4 wk-form4_1738113042.xml 4 8039
2 EX-24 dchang-allogenexsection1.htm EX-24 3812
3 dchang-allogenexsection1001.jpg GRAPHIC 219852
  Complete submission text file 0001737287-25-000004.txt   316177
Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
Chang David D (Reporting) CIK: 0001611024 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 25566302

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)